Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16

BACKGROUND: Chemotherapy in combination with anti-epidermal growth factor receptor (EGFR) antibody is considered a first-line treatment regimen for RAS wild-type and left-sided metastatic colorectal cancer (mCRC), whereas second-line treatment regimens have not yet been established. Few studies have...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasui, H., Okita, Y., Nakamura, M., Sagawa, T., Watanabe, T., Kataoka, K., Manaka, D., Shiraishi, K., Akazawa, N., Okuno, T., Shimura, T., Shiozawa, M., Sunakawa, Y., Ota, H., Kotaka, M., Okuyama, H., Takeuchi, M., Ichikawa, W., Fujii, M., Tsuji, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594013/
https://www.ncbi.nlm.nih.gov/pubmed/37703596
http://dx.doi.org/10.1016/j.esmoop.2023.101636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594013/
https://www.ncbi.nlm.nih.gov/pubmed/37703596
http://dx.doi.org/10.1016/j.esmoop.2023.101636

Ejemplares similares